Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL ER versus METRONIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL ER versus METRONIDAZOLE.
FLAGYL ER vs METRONIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.
750 mg orally once daily for 10 days for bacterial vaginosis.
500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.
None Documented
None Documented
Clinical Note
moderateMetronidazole + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Metronidazole."
Clinical Note
moderateMetronidazole + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Metronidazole."
Clinical Note
moderateMetronidazole + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Metronidazole."
Clinical Note
moderateMetronidazole + Clotrimazole
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
8 hours (range 6-10 hours) in adults; prolonged to 18-20 hours in severe hepatic impairment; requires adjustment in cirrhosis.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal (60-80% unchanged drug), biliary/fecal (6-15% as metabolites, <20% unchanged).
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Metronidazole."